Safety and PK of Single Rising Oral Doses of Olodaterol in Healthy Males

Phase 1, randomised, single-blind trial in chronic obstructive pulmonary disease (COPD) comparing BI 1744 CL with Placebo (2 arms). Primary endpoints: Number of patients with abnormal findings in physical examination at Day 17, Number of patients with clinically significant changes in vital signs and 4 more. Started Jun 2007; status: completed.